View Archive »
About The Cover
An example of invasion ex vivo: 3D reconstruction of optical projection tomography of a representative ER+ HER2- tumour. See Katz et al.
|
|
Table of Contents
Editorial
|
| Destroying cJun Messenger: New Insights into Biological Mechanisms of DNAzyme Function |
|
https://doi.org/10.18632/oncotarget.549
|
| 594-595 |
Research Perspectives
|
| Cyclotherapy: opening a therapeutic window in cancer treatment |
|
https://doi.org/10.18632/oncotarget.524
|
| 596-600 |
|
| Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells |
|
https://doi.org/10.18632/oncotarget.548
|
| 601-607 |
Research Papers
|
| Targeting of Rac GTPases blocks the spread of intact human breast cancer |
|
https://doi.org/10.18632/oncotarget.520
|
| 608-619 |
|
| Clinical utility of geneexpression profiling for tumorsite origin in patients with metastatic or poorly differentiated cancer: impact on diagnosis treatment and survival |
|
https://doi.org/10.18632/oncotarget.521
|
| 620-628 |
|
| ComputerBased Identification of a Novel LIMK1/2 Inhibitor that Synergizes with Salirasib to Destabilize the Actin Cytoskeleton |
|
https://doi.org/10.18632/oncotarget.525
|
| 629-639 |
|
| A composite polymer nanoparticle overcomes multidrug resistance and ameliorates doxorubicinassociated cardiomyopathy |
|
https://doi.org/10.18632/oncotarget.543
|
| 640-650 |
|
| Sox9 is required for prostate development and prostate cancer initiation |
|
https://doi.org/10.18632/oncotarget.531
|
| 651-663 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC